NCT06248008View on ClinicalTrials.gov

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

April 18, 2024

Primary Completion Date

October 15, 2025

Study Completion Date

March 9, 2026

Conditions
Acne
Interventions
DRUG

ASC40

ASC40 tablets orally once daily

Trial Locations (1)

200000

Huashan Hospital Fudan University, Shanghai

Sponsors
All Listed Sponsors
lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY